Rimegepant

Phase 3

PFIZER (PFE)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

9mo

PFEPhase 3$142.7B

Rimegepant Phase 3 Results Expected

Rimegepant• Acute Migraine723

Nov 29Estimated

CT.gov

00%

7mo

PFEPhase 3$142.7B

Rimegepant Phase 3 Results Expected

Rimegepant• Acute Migraine200

Oct 8Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Acute Migraine

View Full Landscape

Drug Information

Target Indication

Acute Migraine

Clinical Trial

NCT04574362

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/25/2022

Vydura

Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Healthcare•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Cyclosporine APhase 3

Renal Transplantation

Insulin LisproPhase 3

Diabetes Mellitus

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline